Reduction in heart failure outcomes with SGLT2 inhibitors irrespective of glycaemic status
Gerstein HC, Sattar N
Lancet Diabetes Endocrinol. 2022;S2213-8587(22)00313-8.
Leggi
Progressive acceleration of insulin exposure over seven days of infusion set wear
Kastner JR, Bailey TS, Strange P, et al.
Diabetes Technol Ther. Pub. online 7 Nov 2022.
Leggi
Evaluation of continuous glucose monitoring-derived person-specific HbA1c in the presence and absence of complications in type 1 diabetes
Xu Y, Oriot P, Dunn TC, et al.
Diabetes Obes Metab. 2022;24(12):2383-2390.
Leggi
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12 months
Guerci B, Giorgino F, Sapin H, et al.
Diabetes Obes Metab. 2022;24(12):2373-2382.
Leggi
Kidney function measures and cardiovascular outcomes in people with diabetes: the Hoorn Diabetes Care System cohort
Dal Canto E, Elders PJM, van der Heijden AA, et al.
Diabetologia. Pub. online 8 Nov 2022.
Leggi
Effects of 26 weeks of treatment with empagliflozin versus glimepiride on the myocardial glucose metabolic rate in patients with type 2 diabetes: The randomized, open-label, crossover, active-comparator FIORE trial
Succurro E ,Vizza P, Papa, et al.
Diabetes Obes Metab. 2022;24(12):2319-2330.
Leggi
Relationship between a novel non–insulin-based metabolic score for insulin resistance (METS‐IR) and coronary artery calcification
Zhenwei Wang, Xiaofang Hui, Huang X, et al.
BMC Endocr Disord. 2022;22(1):274.
Leggi
The relationship between islet autoantibody status and the genetic risk of type 1 diabetes in adult-onset type 1 diabetes
Thomas NJ, Walkey HC, Kaur A, et al.
Diabetologia. Pub. online 10 Nov 2022.
Leggi
